GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Braxia Scientific Corp (XCNQ:BRAX) » Definitions » Loans Receivable

Braxia Scientific (XCNQ:BRAX) Loans Receivable : C$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Braxia Scientific Loans Receivable?

Braxia Scientific's Loans Receivable for the quarter that ended in Dec. 2023 was C$0.00 Mil.


Braxia Scientific Loans Receivable Historical Data

The historical data trend for Braxia Scientific's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Braxia Scientific Loans Receivable Chart

Braxia Scientific Annual Data
Trend Mar21 Mar22 Mar23
Loans Receivable
- - -

Braxia Scientific Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Braxia Scientific Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Braxia Scientific Loans Receivable Related Terms

Thank you for viewing the detailed overview of Braxia Scientific's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Braxia Scientific (XCNQ:BRAX) Business Description

Traded in Other Exchanges
Address
700 Bay Street, Suite 1903, Toronto, ON, CAN, M5G 1Z6
Braxia Scientific Corp is a research-driven medical solutions company that aims to reduce the illness burden of brain-based mental disorders such as depressive disorder among others. It is primarily focused on owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and research activities related to discovering and commercializing novel drugs and delivery methods. The company develops ketamine and psilocybin derivatives and other psychedelic products from its IP development platform.

Braxia Scientific (XCNQ:BRAX) Headlines

No Headlines